FAQ

fontolizumab

Known as: HUZAF, Immunoglobulin G1, Anti-(Human Interferon Gamma) (Human-Mouse Monoclonal Huzaf Gamma-1-Chain), Disulfide with Human-Mouse Monoclonal Huzaf Light Chain, Dimer 
A humanized monoclonal antibody directed against interferon-gamma (IFN-g) with immunomodulatory activity. Fontolizumab binds to and prevents the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2018
01220042018

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Related mentions per year

Related mentions per year

1957-2018
1960198020002020
fontolizumab
antigen binding
Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and…
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
BACKGROUND The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2008
2008
Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome.
Therapeutic antibodies against tumor necrosis factor (TNF) (infliximab) and IFNgamma (fontolizumab) have been developed to treat… (More)
Is this relevant?
2008
2008
Intérêt de l’antiinterféron gamma (fontolizumab) dans la maladie de Crohn (MC) modérée à sévère
alors appari6s avec des sujets t6moins pour des crit~res d'~ge, de sexe et de dur6e de suivi. Les patients qui avaient pr6sent6… (More)
Is this relevant?
2006
2006
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
INTRODUCTION Interferon gamma is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to…
INTRODUCTION This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon gamma antibody, in… (More)
Is this relevant?
Review
2005
Review
2005
Fontolizumab Protein Design Labs.
Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for the potential… (More)
Is this relevant?
Review
2005
Review
2005
Advances in therapeutic approaches to ulcerative colitis and Crohn's disease.
Advances (from 2004 to 2006) in the use of conventional agents include the molecular mechanisms of action, which have… (More)
Is this relevant?
2004
2004
Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms.
Three-dimensional structures were determined for two crystal forms (orthorhombic P2(1)2(1)2(1) and monoclinic C2) of the Fab from… (More)
Is this relevant?
Review
2004
Review
2004
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
The chimeric monoclonal antibody to tumor necrosis factor (TNF), infliximab, is an effective therapy for Crohn's disease. However… (More)
Is this relevant?